Citations

Clear

1575 citation(s) found for "Im, Gene".

AAPM Task Group Report 272: Comprehensive acceptance testing and evaluation of fluoroscopy imaging systems
Goode, Allen R. , Corwin, Frank, Fisher, Ryan , Balter, Stephen , Wunderle, Kevin , Schueler, Beth A. , Kim, Don‐Soo , Zhou, Yifang , Jenkins, Peter , Mahmood, Usman , Lin, Teh, Zhao, Hui , Park, Mi‐Ae , Trianni, Annalisa , Lendle, Markus, Kuhls‐Gilcrist, Andrew, Jans, J. C., Desponds, L. , Banasiak, Gene, Backes, Steve, Snyder, Angela, Lu, Minghui , Gonzalez, Scott, Lin, Pei‐Jan Paul , Zhang, Jie , Jenkins, Peter A., Snyder, Carl

Mayo Clinic

Medical Physics | January 15, 2022 | Volume: 49 | Issue: 4 | Pages: No page available

10.1002/mp.15429 | PMID 35032394 Get It

AbstractModern fluoroscopes used for image guidance have become quite complex. Adding to this complexity are the many regulatory and accreditation requirements that must be fulfilled during acceptance testing of a new unit. Further, some of these acceptance tests have pass/fail criteria, whereas others do not, making acceptance testing a subjective and time‐consuming task. The AAPM Task Group 272 Report spells out the details of tests that are required and gives visibility to some of the tests that while not yet required are recommended as good practice. The organization of the report begins with the most complicated fluoroscopes used in interventional radiology or cardiology and continues with general fluoroscopy and mobile C‐arms. Finally, the appendices of the report provide useful information, an example report form and topics that needed their own section due to the level of detail.
Interorgan crosstalk in pancreatic islet function and pathology
Evans, Ronald M. , Wei, Zong , Wei, Zong , Evans, Ronald M

Mayo Clinic

FEBS Letters | January 11, 2022 | Volume: 596 | Issue: 5 | Pages: 607-619

10.1002/1873-3468.14282 | PMID 35014695 Get It

Pancreatic β cells secrete insulin in response to glucose, a process that is regulated at multiple levels, including a network of input signals from other organ systems. Impaired islet function contributes to the pathogenesis of type 2 diabetes mellitus (T2DM), and targeting inter‐organ communications, such as GLP‐1 signalling, to enhance β‐cell function has been proven to be a successful therapeutic strategy in the last decade. In this review, we will discuss recent advances in inter‐organ communication from the metabolic, immune and neural system to pancreatic islets, their biological implication in normal pancreas endocrine function and their role in the (mal)adaptive responses of islet to nutrition‐induced stress.
BRD9 regulates interferon-stimulated genes during macrophage activation via cooperation with BET protein BRD4
Ahmed, Nasiha S. , Ho, Josephine , Burns, Mannix J. , Wei, Zong , Downes, Michael , Evans, Ronald M. , Hargreaves, Diana C. , Gatchalian, Jovylyn , Burns, Mannix J , Wei, Zong , Downes, Michael , Evans, Ronald M , Hargreaves, Diana , Hah, Nasun

Mayo Clinic

Proceedings of the National Academy of Sciences | January 4, 2022 | Volume: 119 | Issue: 1 | Pages: No page available

10.1073/pnas.2110812119 | PMID 34983841 Get It

Significance Macrophages regulate many aspects of the innate immune response and the activation of adaptive immunity following exposure to microbial ligands. However, macrophages can also contribute to inflammation underlying diseases such as atherosclerosis and obesity. Epigenetic regulators control inflammatory gene regulation and, as such, are potential targets for modulation of the inflammatory response. Here, we show that inhibitors and degraders of the bromodomain protein BRD9, a subunit of the noncanonical BAF complex, limit inflammation by specifically blocking the induction of interferon-stimulated genes. This effect overlaps with the transcriptional responses with the BET inhibitor JQ1 but affects fewer genes and is more specific in scope. Our results suggest that BRD9 inhibitors/degraders may be therapeutically relevant agents to limit interferon-associated inflammation.
Chimeric RNA: DNA TracrRNA Improves Homology-Directed Repair In Vitro and In Vivo
Simone, Brandon W. , Daby, Camden L. , Ata, Hirotaka , Restrepo-Castillo, Santiago , Kar, Bibekananda , Gendron, William A.C. , Martínez-Gálvez, Gabriel, Kar, Bibekananda , Castillo, Santiago R , Lee, Han , Martínez‐Gálvez, Gabriel , Clark, Karl J. , Ekker, Stephen C.

Mayo Clinic

The CRISPR Journal | December 22, 2021 | Volume: 5 | Issue: 1 | Pages: 40-52

10.1089/crispr.2021.0087 | PMID 34935462 Get It

Nearly 90% of human pathogenic mutations are caused by small genetic variations, and methods to correct these errors efficiently are critically important. One way to make small DNA changes is providing a single-stranded oligo deoxynucleotide (ssODN) containing an alteration coupled with a targeted double-strand break (DSB) at the target locus in the genome. Coupling an ssODN donor with a CRISPR-Cas9-mediated DSB is one of the most streamlined approaches to introduce small changes. However, in many systems, this approach is inefficient and introduces imprecise repair at the genetic junctions. We herein report a technology that uses spatiotemporal localization of an ssODN with CRISPR-Cas9 to improve gene alteration. We show that by fusing an ssODN template to the trans-activating RNA (tracrRNA), we recover precise genetic alterations, with increased integration and precision in vitro and in vivo . Finally, we show that this technology can be used to enhance gene conversion with other gene editing tools such as transcription activator like effector nucleases.
De novo coding variants in the AGO1 gene cause a neurodevelopmental disorder with intellectual disability
Schalk, Audrey , Cousin, Margot A. , Dsouza, Nikita R., Challman, Thomas D. , Wain, Karen E. , Powis, Zöe , Minks, Kelly Q., Trimouille, Aurélien , Lasseaux, Eulalie , Michaud, Vincent , Van‐Gils, Julien , Spataro, Nino , Gabau, Elizabeth, Stolerman, Elliot , Washington, Camerun , Louie, Ray, Lanpher, Brendan C. , Kemppainen, Jennifer L., Innes, Micheil, Kooy, R. Frank , Goldenberg, Alice, Lecoquierre, François , Vera, Gabriella , Sheidley, Beth Rosen , Achkar, Christelle Moufawad El , Park, Meredith, Hamdan, Fadi F. , Michaud, Jacques L. , Lewis, Ann J., Zweier, Christiane , Wagner, Matias , Weigand, Heike, Journel, Hubert, Keren, Boris , Passemard, Sandrine , Mignot, Cyril , Brilstra, Eva H. , Itzikowitz, Gina, O’Heir, Emily , Allen, Jake, Donald, Kirsten A. , Korf, Bruce R. , Skelton, Tammi, Rudy, Natasha L. , Dobyns, William B. , Foss, Kimberly , Bosanko, Katherine A. , Alembik, Yves, Durand, Benjamin , Mau‐Them, Frédéric Tran , Ranza, Emmanuelle , Blanc, Xavier , Torti, Erin , Millan, Francisca , Dameron, Amy, Tokita, Mari, Zimmermann, Michael T. , Klee, Eric W. , Piton, Amélie , Gérard, Bénédicte , Ruiz, Anna , Stolerman, Elliot , Kooy, Frank , Lecoquierre, Francois , Reis, André , Wagner, Matias , Passemard, Sandrine , Tran Mau-Them, Frederic , Klee, Eric W , Piton, Amelie , Zimmermann, Michael T , Lacombe, Didier , Angelini, Chloé , Louie, Raymond J. , Meuwissen, Marije E. C. , Goldenberg, Alice , Diderich, Karin E. M. , Reis, André , Gassen, Koen L.I. van , Thompson, Michelle L. , Robin, Nathaniel H. , Zárate, Yuri A. , Antonarakis, Stylianos E. , McWalter, Kirsty

Mayo Clinic

Journal of Medical Genetics | December 20, 2021 | Volume: 59 | Issue: 10 | Pages: 965-975

10.1136/jmedgenet-2021-107751 | PMID 34930816 Get It

Background High-impact pathogenic variants in more than a thousand genes are involved in Mendelian forms of neurodevelopmental disorders (NDD). Methods This study describes the molecular and clinical characterisation of 28 probands with NDD harbouring heterozygous AGO1 coding variants, occurring de novo for all those whose transmission could have been verified (26/28). Results A total of 15 unique variants leading to amino acid changes or deletions were identified: 12 missense variants, two in-frame deletions of one codon, and one canonical splice variant leading to a deletion of two amino acid residues. Recurrently identified variants were present in several unrelated individuals: p.(Phe180del), p.(Leu190Pro), p.(Leu190Arg), p.(Gly199Ser), p.(Val254Ile) and p.(Glu376del). AGO1 encodes the Argonaute 1 protein, which functions in gene-silencing pathways mediated by small non-coding RNAs. Three-dimensional protein structure predictions suggest that these variants might alter the flexibility of the AGO1 linker domains, which likely would impair its function in mRNA processing. Affected individuals present with intellectual disability of varying severity, as well as speech and motor delay, autistic behaviour and additional behavioural manifestations. Conclusion Our study establishes that de novo coding variants in AGO1 are involved in a novel monogenic form of NDD, highly similar to the recently reported AGO2 -related NDD.
High Prevalence of Gene Fusions and Copy Number Alterations in Pediatric Radiation Therapy-Induced Papillary and Follicular Thyroid Carcinomas
Hess, Jennifer , Newbern, Dorothee , Beebe, Kristen , Walsh, Alexandra , Schafernak, Kristian T. , Hess, Jennifer R , Beebe, Kristen L, Walsh, Alexandra M , Schafernak, Kristian

Mayo Clinic

Thyroid® | December 17, 2021 | Volume: 32 | Issue: 4 | Pages: 411-420

10.1089/thy.2021.0217 | PMID 34915766 Get It

Background: Childhood cancer survivors and bone marrow transplant recipients treated with radiation therapy (RT) are at increased risk for subsequent thyroid cancer. However, the genetic landscape of pediatric thyroid cancer, both primary and RT-induced, remains poorly defined, as pediatric papillary thyroid carcinoma (PTC) has been understudied compared with adults and data on pediatric follicular thyroid carcinoma (FTC) are virtually nonexistent. The objective of this study was to characterize and compare the molecular profiles of pediatric RT-induced PTC and FTC cases with primary pediatric thyroid cancers. Methods: A total of 41 differentiated thyroid carcinomas (11 RT cases and 30 primary cases) from 37 patients seen at Phoenix Children's Hospital between January 1, 2010 and December 31, 2019 were evaluated by targeted next-generation sequencing and/or BRAF immunohistochemistry. Results: Eighty-six percent (6/7) of RT-PTC harbored a gene fusion (GF) compared with 56% (14/25) of primary PTC; 14% (1/7) of RT-PTC had a single-nucleotide variant (SNV; specifically, a point mutation in the DICER1 gene ) compared with 44% (11/25) of primary PTC (all of the latter had the BRAF V600E mutation). An exceedingly rare ROS1 fusion was identified in a child with RT-PTC. With respect to FTC, copy number alterations (CNAs) were seen in 75% (3/4) of RT cases compared with 40% (2/5) of primary cases. None of the RT-FTC had SNVs compared with 100% (5/5) of primary FTC. Conclusions: In children, the molecular profile of subsequent RT-induced thyroid cancers appears to differ from primary (sporadic and syndromic) cases, with a high prevalence of GFs in RT-PTC (similar to PTC occurring after the Chernobyl nuclear reactor accident) and CNAs in RT-FTC. A better understanding of the molecular mechanisms underlying these cancers may lead to more accurate diagnosis, prognosis, and treatment, as some of the genomic alterations are potentially targetable.
A New Gene Set Identifies Senescent Cells and Predicts Senescence-Associated Pathways Across Tissues
Khosla, Sundeep , Saul, Dominik , Kosinsky, Robyn Laura , Atkinson, Elizabeth J. , LeBrasseur, Nathan K. , Pignolo, Robert J. , Robbins, Paul D. , Niedernhofer, Laura J. , Ikeno, Yuji , Jurk, Diana , Xue, Ailing, Kirkland, James L. , Khosla, Sundeep , Jurk, Diana , LeBrasseur, Nathan K , Niedernhofer, Laura J , Robbins, Paul D , Kosinsky, Robyn Laura , Saul, Dominik , Doolittle, Madison L. , Zhang, Xu , Passos, João F. , Hickson, LaTonya J. , Monroe, David G. , Tchkonia, Tamar , Farr, Joshua N.

Mayo Clinic

No container title available | December 13, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-1034608/v1 Get It

Abstract Although cellular senescence is increasingly recognized as driving multiple age-related co-morbidities through the senescence-associated secretory phenotype (SASP), in vivo senescent cell identification, particularly in bulk or single cell RNA-sequencing (scRNA-seq) data remains challenging. Here, we generated a novel gene set (SenMayo) and first validated its enrichment in bone biopsies from two aged human cohorts. SenMayo also identified senescent cells in aged murine brain tissue, demonstrating applicability across tissues and species. For direct validation, we demonstrated significant reductions in SenMayo in bone following genetic clearance of senescent cells in mice, with similar findings in adipose tissue from humans in a pilot study of pharmacological senescent cell clearance. In direct comparisons, SenMayo outperformed all six existing senescence/SASP gene sets in identifying senescent cells across tissues and in demonstrating responses to senescent cell clearance. We next used SenMayo to identify senescent hematopoietic or mesenchymal cells at the single cell level from publicly available human and murine bone marrow/bone scRNA-seq data and identified monocytic and osteolineage cells, respectively, as showing the highest levels of senescence/SASP genes. Using pseudotime and cellular communication patterns, we found senescent hematopoietic and mesenchymal cells communicated with other cells through common pathways, including the Macrophage Migration Inhibitory Factor (MIF) pathway, which has been implicated not only in inflammation but also in immune evasion, an important property of senescent cells. Thus, SenMayo identifies senescent cells across tissues and species with high fidelity. Moreover, using this senescence panel, we were able to characterize senescent cells at the single cell level and identify key intercellular signaling pathways associated with these cells, which may be particularly useful for evolving efforts to map senescent cells (e.g., SenNet). In addition, SenMayo represents a potentially clinically applicable panel for monitoring senescent cell burden with aging and other conditions as well as in studies of senolytic drugs.
Interactions Between Folate Intake and Genetic Predictors of Gene Expression Levels Associated with Colorectal Cancer Risk
Petersen, Paneen S., Weinstein, Stephanie J. , Figueiredo, Jane C. , Casey, Graham , Peters, Ulrike , Slattery, Martha L. , Li, Li , Gruber, Stephen B. , Woods, Michael O. , Gallinger, Steven , Berndt, Sonja I. , Nan, Hongmei , Nassir, Rami , Lindor, Noralane M. , Kim, Andrew E, Gauderman, W. James, Nassir, Rami , Nan, Hongmei , Haas, Cameron B. , Su, Yu-Ru , Wang, Xiaoliang , Bien, Stephanie A. , Lin, Yi , Albanes, Demetrius , Jenkins, Mark A. , Newcomb, Polly A. , Marchand, Loı̈c Le , Campbell, Peter T. , Moreno, Vı́ctor , Potter, John D. , Sakoda, Lori C. , Chan, Andrew T. , Giles, Graham G. , Milne, Roger L. , Rennert, Gad , Hayes, Richard B. , Huang, Wen‐Yi , Wolk, Alicja , White, Emily , Lewinger, Juan Pablo , Conti, David V. , Buchanan, Daniel D.

Mayo Clinic

No container title available | December 9, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-1097039/v1 Get It

Abstract Background Observational studies have shown higher folate consumption to be associated with lower risk of colorectal cancer (CRC). Understanding whether and how genetic risk factors interact with folate could further elucidate the underlying mechanism. Aggregating functionally relevant genetic variants in set-based variant testing has higher power to detect gene-environment (GxE) interactions and may provide information on the underlying biological pathway. Objective We investigated interactions between folate consumption and predicted gene expression on colorectal cancer risk across the genome. Methods We used variant weights from the PrediXcan models of colon tissue-specific gene expression as a priori variant information for a set-based GxE approach. We harmonized total folate intake (mcg/day) based on dietary intake and supplemental use across cohort and case-control studies and calculated sex and study specific quantiles. Analyses were performed using a mixed effects score tests for interactions between folate and genetically predicted expression of 4,839 genes with available genetically predicted expression. We meta-analyzed results across 23 studies for a total of 13,498 cases with colorectal tumors and 13,918 controls of European ancestry. Results We found suggestive evidence of interaction with folate intake for genes including glutathione S-Transferase Alpha 1 (GSTA1; p=4.3E-4), Tonsuko Like, DNA Repair Protein (TONSL; p=4.3E-4), and Aspartylglucosaminidase (AGA: p=4.5E-4). Glutathione is an antioxidant, preventing cellular damage and is a downstream metabolite of homocysteine and metabolized by GSTA1. TONSL is part of a complex that functions in the recovery of double strand breaks and AGA plays a role in lysosomal breakdown of glycoprotein. Conclusion We identified three genes involved in preventing or repairing DNA damage that may interact with folate consumption to alter CRC risk.
Gene-mapping study of extremes of cerebral small vessel disease reveals TRIM47 as a strong candidate
Mishra, Aniket , Duplàa, Cécile , Suzuki, Hideaki , Li, Shuo , Bartz, Traci M. , Jian, Xueqiu , Zhao, Wei , Hofer, Edith , Wittfeld, Katharina , Bis, Joshua C, Adams, Hieab H.H. , Satizábal, Claudia L. , Gottesman, Rebecca F., Gampawar, Piyush , Weiß, Stefan , Yu, Miao , Lopez, Oscar L., Vernooij, Meike W. , Soumaré, Aïcha , Smith, Jennifer A. , Zhu, Yi‐Cheng , Rotter, Jerome I. , Dufouil, Carole , Maniega, Susana Muñoz , Lathrop, Mark, Boerwinkle, Erik, Schmidt, Reinhold, Ihara, Masafumi , Joutel, Anne , Tournier‐Lasserve, Elisabeth , Mosley, Thomas H. , DeCarli, Charles , Tzourio, Christophe , Kardia, Sharon L. R., Teumer, Alexander , Schmidt, Helena , Wardlaw, Joanna M. , Fornage, Myriam , Guðnason, Vilmundur , Longstreth, W.T. , Couffinhal, Thierry , Debette, Stéphanie , Zhao, Wei , Sargurupremraj, Muralidharan , DeCarli, Charles , Suzuki, Hideaki , Sargurupremraj, Muralidharan , Bülow, Robin , Weiss, Stefan , Völker, Uwe , Smith, Jennifer A , Yang, Qiong , Amouyel, Philippe , Tzourio, Christophe , Teumer, Alexander , van Duijn, Cornelia M , Matthews, Paul M , Debette, Stephanie , Wardlaw, Joanna Marguerite , Adams, Hieab H H , Satizabal, Claudia L , Rotter, Jerome I , Vojinović, Dina , Zilhäo, Nuno R. , Harris, Sarah , Auwera, Sandra Van der , Luciano, Michelle , Bis, Joshua C, Bastin, Mark E. , Beiser, Alexa , Völker, Uwe , Kacprowski, Tim , Knopman, David S. , Morris, Zoë , Hernández, Maria del Carmen Valdés , Mazoyer, Bernard , Launer, Lenore J. , Deary, Ian J. , Amouyel, Philippe , Psaty, Bruce M. , Grabe, Hans Jörgen , Duijn, Cornelia M. van , Ikram, M. Arfan , Seshadri, Sudha , Matthews, Paul M.

Mayo Clinic

Brain | December 8, 2021 | Volume: 145 | Issue: 6 | Pages: 1992-2007

10.1093/brain/awab432 | PMID 35511193 Get It

Abstract Cerebral small vessel disease is a leading cause of stroke and a major contributor to cognitive decline and dementia, but our understanding of specific genes underlying the cause of sporadic cerebral small vessel disease is limited. We report a genome-wide association study and a whole-exome association study on a composite extreme phenotype of cerebral small vessel disease derived from its most common MRI features: white matter hyperintensities and lacunes. Seventeen population-based cohorts of older persons with MRI measurements and genome-wide genotyping (n = 41 326), whole-exome sequencing (n = 15 965), or exome chip (n = 5249) data contributed 13 776 and 7079 extreme small vessel disease samples for the genome-wide association study and whole-exome association study, respectively. The genome-wide association study identified significant association of common variants in 11 loci with extreme small vessel disease, of which the chr12q24.11 locus was not previously reported to be associated with any MRI marker of cerebral small vessel disease. The whole-exome association study identified significant associations of extreme small vessel disease with common variants in the 5′ UTR region of EFEMP1 (chr2p16.1) and one probably damaging common missense variant in TRIM47 (chr17q25.1). Mendelian randomization supports the causal association of extensive small vessel disease severity with increased risk of stroke and Alzheimer’s disease. Combined evidence from summary-based Mendelian randomization studies and profiling of human loss-of-function allele carriers showed an inverse relation between TRIM47 expression in the brain and blood vessels and extensive small vessel disease severity. We observed significant enrichment of Trim47 in isolated brain vessel preparations compared to total brain fraction in mice, in line with the literature showing Trim47 enrichment in brain endothelial cells at single cell level. Functional evaluation of TRIM47 by small interfering RNAs-mediated knockdown in human brain endothelial cells showed increased endothelial permeability, an important hallmark of cerebral small vessel disease pathology. Overall, our comprehensive gene-mapping study and preliminary functional evaluation suggests a putative role of TRIM47 in the pathophysiology of cerebral small vessel disease, making it an important candidate for extensive in vivo explorations and future translational work.
The protective gene dose effect of the APOEε2 allele on gray matter volume in cognitively unimpaired individuals
Salvadó, Gemma , Ferreira, Daniel , Operto, Grégory , Cumplido‐Mayoral, Irene , Falcón, Carles , Vilor‐Tejedor, Natàlia , Minguillón, Carolina , Groot, Colin , Barkhof, Frederik , Scheltens, Philip , Ossenkoppele, Rik , Kern, Silke , Zettergren, Anna , Hort, Jakub , Stomrud, Erik , Westen, Danielle van , Hansson, Oskar , Westman, Eric , Gispert, Juan Domingo , ADNI, ALFA study†, BioFINDER,, Crous‐Bou, Marta , Arenaza-Urquijo, Eider M , Cacciaglia, Raffaele , Falcon, Carles , Vilor-Tejedor, Natàlia , Minguillon, Carolina , Groot, Colin , van der Flier, Wiesje M , Barkhof, Frederik , Scheltens, Philip , Ossenkoppele, Rik , Skoog, Ingmar , Stomrud, Erik , van Westen, Danielle , Hansson, Oskar , Molinuevo, José Luis , Wahlund, Lars-Olof , Westman, Eric , Gispert, Juan Domingo , Ferreira, Daniel , Hort, Jakub , Arenaza‐Urquijo, Eider M. , Flier, Wiesje M. van der , Skoog, Ingmar , Molinuevo, José Luís , Wahlund, Lars‐Olof , ADNI, ALFA study†, BioFINDER,

Mayo Clinic

Alzheimer's & Dementia | December 8, 2021 | Volume: 18 | Issue: 7 | Pages: 1383-1395

10.1002/alz.12487 | PMID 34877786 Get It

AbstractIntroductionHarboring two copies of the apolipoprotein E (APOE) ε2 allele strongly protects against Alzheimer's disease (AD). However, the effect of this genotype on gray matter (GM) volume in cognitively unimpaired individuals has not yet been described.MethodsMulticenter brain magnetic resonance images (MRIs) from cognitively unimpaired ε2 homozygotes were matched (1:1) against all other APOE genotypes for relevant confounders (n = 223). GM volumes of ε2 genotypic groups were compared to each other and to the reference group (APOE ε3/ε3).ResultsCarrying at least one ε2 allele was associated with larger GM volumes in brain areas typically affected by AD and also in areas associated with cognitive resilience. APOE ε2 homozygotes, but not APOE ε2 heterozygotes, showed larger GM volumes in areas related to successful aging.DiscussionIn addition to the known resistance against amyloid‐β deposition, the larger GM volumes in key brain regions may confer APOE ε2 homozygotes additional protection against AD‐related cognitive decline.